BRAF inhibitor treatment in classic hairy cell leukemia: a long-term follow-up study of patients treated outside clinical trials

Leukemia. 2020 May;34(5):1454-1457. doi: 10.1038/s41375-019-0646-y. Epub 2019 Nov 18.
No abstract available

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Dose-Response Relationship, Drug
  • Follow-Up Studies
  • Humans
  • Imidazoles / administration & dosage
  • Leukemia, Hairy Cell / drug therapy*
  • Leukemia, Hairy Cell / genetics
  • Leukemia, Hairy Cell / pathology
  • Mutation
  • Oximes / administration & dosage
  • Prognosis
  • Protein Kinase Inhibitors / therapeutic use*
  • Proto-Oncogene Proteins B-raf / antagonists & inhibitors*
  • Proto-Oncogene Proteins B-raf / genetics
  • Retrospective Studies
  • Survival Rate
  • Vemurafenib / administration & dosage

Substances

  • Imidazoles
  • Oximes
  • Protein Kinase Inhibitors
  • Vemurafenib
  • BRAF protein, human
  • Proto-Oncogene Proteins B-raf
  • dabrafenib